A chemoimmunotherapy regimen with only 3 cycles of chemotherapy was found to be efficacious in a phase 2 trial that sought to reduce treatment-related MDS/AML in patients with CLL.
At 4 years, there was no significant difference in overall survival.
The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.
GAB1 inhibitors impaired migration of chronic lymphocytic leukemia cells and induced apoptosis.
Patients with chronic lymphocytic leukemia had a significantly reduced antibody response rate when compared with healthy individuals.
Researchers sought to determine factors that may impact infection risk in patients with CLL.
A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
Investigators conducted a randomized controlled trial to determine whether the addition of ublituximab to treatment with ibrutinib improved outcomes in patients with relapsed or refractory chronic lymphocytic leukemia.
Researchers sought to describe a potential link between treatment with lenalidomide and development of B-cell ALL in patients with CLL.
A team of investigators conducted a phase 2 trial to assess outcomes of hepatitis C virus and varicella zoster vaccination in patients with treatment-naive CLL or those on BTK inhibitor therapy.
